Paul Reider serves as the Chief Commercial Officer at Coherus BioSciences, Inc., a position he has held since joining the company in 2017. With a robust background in the biopharmaceutical industry, Reider has been instrumental in driving the commercialization strategies for Coherus, a company focused on developing and commercializing biosimilar therapeutics. His leadership has been pivotal in the successful launch of several key products, including UDENYCA, a biosimilar to Neulasta, which has significantly expanded the company's market presence. Before joining Coherus BioSciences, Reider held various high-level positions at leading pharmaceutical companies. He spent over a decade at Amgen, where he served as Vice President of Sales and Marketing, overseeing the launch and growth of several blockbuster oncology products. His tenure at Amgen was marked by his ability to develop and execute strategic market entry plans that maximized product penetration and revenue growth. Prior to Amgen, Reider worked at Johnson & Johnson, where he honed his skills in sales, marketing, and business development, contributing to the company's success in the competitive pharmaceutical landscape. In his role at Coherus, Reider is responsible for overseeing the company's commercial operations, including sales, marketing, and market access strategies. His strategic vision and deep understanding of the biopharmaceutical market have been crucial in navigating the complex regulatory and competitive environment. Under his leadership, Coherus has continued to expand its portfolio and strengthen its position in the biosimilar market, aiming to provide more affordable and accessible treatment options to patients worldwide.